Cidara Therapeutics ( (CDTX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cidara Therapeutics’ stock is on the rise following a substantial contract with BARDA worth up to $339 million, aimed at advancing their CD388 program. This funding is set to boost market opportunities and support key projects, such as developing a single-injection profile. Analysts remain optimistic, maintaining a Strong Buy consensus, reflecting the positive outlook from these strategic moves.
More about Cidara Therapeutics
YTD Price Performance: 260.81%
Average Trading Volume: 728,785
Technical Sentiment Signal: Buy
Current Market Cap: $2.5B
For further insights into CDTX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.